摘要
目的:观察鳖甲煎丸联合穴位注射治疗原发性肝癌轻中度癌痛的临床疗效。方法:将80例经确诊为原发性肝癌患者随机分为对照组和治疗组。对照组轻度癌痛患者给予吲哚美辛肠溶片口服,25 mg/次,3次/d。中度癌痛患者给予盐酸曲马多缓释片口服,100 mg/次,2次/d。治疗组轻度、中度癌痛患者均给予鳖甲煎丸口服,3 g/次,每日3次。双侧足三里穴位注射复方苦参注射液各2 ml,隔日1次。4周为一个疗程。一个疗程后,观察两组患者治疗前后疼痛评分变化,疼痛缓解率比较,治疗前后生存质量评价,治疗前后饮食量与体重变化,治疗前后肝功能、甲胎蛋白定量测定,以及记录不良反应发生情况。结果:治疗后,两组患者的疼痛评分均降低,治疗组患者的疼痛评分显著低于对照组,差异有统计学意义(P <0.05);治疗组疼痛缓解率为85%,对照组疼痛缓解率为72.5%,差异有统计学意义(P <0.05);治疗组在日常生活、情绪、行走能力、日常工作、与他人关系、睡眠、生活兴趣方面,因疼痛导致的影响均小于对照组,差异均有统计学意义(P <0.05);治疗组食量增加高于对照组,差异有统计学意义(P <0.05);治疗后两组患者体重变化治疗组小于对照组,比较差异有统计学意义(P <0.05);治疗组患者肝功能、甲胎蛋白改善均优于对照组,且差异均有统计学意义(P <0.05);治疗组不良反应发生率为30%,对照组不良反应发生率为65%,差异有统计学意义(P <0.05)。结论:鳖甲煎丸联合针刺与穴位注射治疗原发性肝癌轻中度癌痛的疗效确切,能明显改善化疗后患者的生存质量,减少不良反应发生,值得在临床上推广应用。
Objective: To observe the clinical efficacy of Biejiajian Pills and acupoint injection in treating mild-moderate cancer pain of primary liver cancer. Methods: 80 patients with primary liver cancer were randomly and equally allocated into treatment group or control group. The patients of mild cancer pain in the control group were given Indometacin Enteric-coated Tablets orally(25 mg/time, tid), and the patients of moderate cancer pain in the control group were given Tramadol Hydrochloride Sustained-release Tablets orally(100 mg/time, bid). Patients with mild and moderate cancer pain allocated into treatment group were treated by Biejiajian Pills orally(3 g/time, tid) and Compound Sophorae injection to bilateral acupoints Zusanli(ST 36)(4 ml/time, qod). After a course treatment of 4 weeks, the scores of cancer pain, effective rate of pain relief, life quality of cancer patients, nutritional status, hepatic function and alpha fetal protein test, and adverse reactions were observed and compared after the treatment cycles. Results: After the treatment, the pain scores of the patients in the two groups decreased, and the pain score of the patients in the observation group was significantly lower than that of the patients in the control group(P < 0.05). The effective rates of pain relief of the patients in the observation group and the control group were respectively 85% and 72.5%(P < 0.05). Nutritional status of the observation group was better than that of the control group, and the difference was statistically significant(P < 0.05). The improvement of hepatic function and alpha fetal protein test in the observation group was better than that of control group(P < 0.05). The incidence rates of adverse actions in the treatment group were all lower than the control group. The observation group was 30%, and the control group was 65%(P < 0.05). Conclusion: Biejiajian Pills and acupoint injection may effectively and safely relieve the level of cancer pain and improve quality of life in patients with primary liver cancer.Res
作者
李枝锦
吴平财
Li Zhijin;Wu Pingcai(Fourth Department of Internal Medicine,Haikou Hospital of Traditional Chinese Medicine,Haikou 570216,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2019年第3期506-511,共6页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
海南省科学技术厅海南省自然科学基金(817387):中医宏观辨证结合胃黏膜微观辨证论治脾虚湿浊型慢性萎缩性胃炎临床研究,负责人:李枝锦
关键词
原发性肝癌
癌痛
鳖甲煎丸
复方苦参注射液
穴位注射
Primary liver cancer
cancer pain
Biejiajian Pills
compound Sophorae injection
acupoint injection
